Rozlytrek, approved Aug. 15, targets solid tumors that show rare genetic defects called NTRK gene fusions and ROS1-positive non-small cell lung cancer.
Eli Lilly and Bayer’s drug Vitrakvi is priced at $32,800 per month. It also treats tumors with NTRK gene fusions.
More articles on pharmacy:
CMS to cover CAR-T therapy nationwide
Colombia fines Pfizer $25K for drug price inflation
Jefferson Healthcare opens retail specialty pharmacy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.